KRAS and non-small cell lung carcinoma: In particular, a significant positive correlation between MET and PD-L1 expression was consistently observed in NSCLC tissues with either a KRAS mutation (n = 93) (r = 0.299, p = 0.004) or without KRAS mutation/EGFR mutation/ALK translocation (n = 152) (r = 0.349, p < 0.001), although a statistically significant positive correlation was not seen in those with an EGFR mutation (n = 41) (Figure 5E–G).